Figure 1. Impact of ARMS2 polymorphisms on the response of patients with cCSC to RFPDT. The proportion of patients with a good response to reduced-fluence
photodynamic therapy (RFPDT) was statistically significantly higher in the homozygous major allele group (GG) compared to
carriers of the minor allele (GT+TT). *p<0.05 (chi-square test).